Fig. 5

LncGHRLOS inhibits the tumorigenesis of CRC in vitro and in vivo. (A) LncGHRLOS mRNA expression was analyzed by qRT-PCR in normal intestinal mucosal epithelial cells and 6 CRC cell lines, and LncGHRLOS was down-regulated in most cell lines. (B) The effect of HT-29 cell viability after CCK-8 detection. (C-D) Wound healing test after overexpression and LncGHRLOS knockdown, injury measurement after 24 H, HT-29 cell line, original magnification :40×, Scale :100 μm. (E) Transwell migration assay was used to detect the effect of LncGHRLOS overexpression and knocked down on cell migration in HT-29 cell line. (F) The tumor formation model of nude mice was made using HCT-116 cells. The tumor volume was monitored every 2 days from day 6 to day 20 after cell inoculation, and the curve was drawn. Overexpression of LncGHRLOS resulted in reduced tumor volume (G) and weight (H). (I) Changes in the survival time of mice. After overexpression of LncGHRLOS, the survival time of mice was prolonged. (J) The number of Ki-67 positive cells in tumor sections was detected by IHC. There were fewer Ki-67 positive cells in tumors with LncGHRLOS overexpression. (K) ROC curve shows that LncGHRLOS has a good diagnostic value for CRC. The area under the curve was 0.7664. (L) the survival curve of CRC patients was drawn combined with the follow-up information of patients. CRC patients with high expression of LncGHRLOS had a better prognosis